PTEN

Genetic and imaging data support the idea that lower-than-usual levels of the tumor suppressor gene PTEN can drive the formation of some ovarian cancers.

The patent application was filed by Montefiore Medical Center's Sanjay Goel and John Mariadason, who discovered the association between mutations in the PIK3CA and PTEN genes and a lack of response to EGFR inhibitors.

Data presented by Myriad at AACR support the "hypothesis that PTEN status predicts outcome after radical prostatectomy, and suggest further, that PTEN may be a clinically important molecular marker for defining aggressive prostate cancer."

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.